- Home
- OPFI vs RLMD Comparison
OPFI vs RLMD Comparison
Compare OPFI & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OPFI | RLMD |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.2M | 319.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OPFI | RLMD |
|---|---|---|
| Price | $9.91 | $3.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $13.50 | $9.00 |
| AVG Volume (30 Days) | 468.5K | ★ 527.2K |
| Earning Date | 03-04-2026 | 11-13-2025 |
| Dividend Yield | ★ 2.52% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $335,423,000.00 | N/A |
| Revenue This Year | $120.32 | N/A |
| Revenue Next Year | $10.85 | N/A |
| P/E Ratio | $72.24 | ★ N/A |
| Revenue Growth | ★ 28.69 | N/A |
| 52 Week Low | $7.54 | $0.24 |
| 52 Week High | $17.73 | $5.12 |
Technical Indicators
Market Signals| Indicator | OPFI | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.68 | 47.27 |
| Support Level | $9.64 | $3.59 |
| Resistance Level | $10.26 | $4.08 |
| Average True Range (ATR) | 0.31 | 0.32 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 19.75 | 40.96 |
Price Performance
Historical ComparisonAbout OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.